ライフサイエンスコーパス: ischaemic heart disease

1 effects of air pollution in individuals with ischaemic heart disease.

2 are therefore a novel therapeutic target in ischaemic heart disease.

3 ar disease and two (Hong Kong and Macao) had ischaemic heart disease.

4 patho-vagal transmission in hypertension and ischaemic heart disease.

5 neurons, represents a 'neural signature' of ischaemic heart disease.

6 One patient on placebo died of ischaemic heart disease.

7 Chronic angina is a common manifestation of ischaemic heart disease.

8 he treatment of heart failure resulting from ischaemic heart disease.

9 towards resident-cell-based therapy in human ischaemic heart disease.

10 tions for the management of hypertension and ischaemic heart disease.

11 , chronic obstructive pulmonary disease, and ischaemic heart disease.

12 ase (ECSOD) may predispose human carriers to ischaemic heart disease.

13 sed for the treatment of hyperlipidaemia and ischaemic heart disease.

14 ceived nicorandil for symptomatic control of ischaemic heart disease.

15 nfer benefits in models of heart failure and ischaemic heart disease.

16 atment of cardiovascular disease, especially ischaemic heart disease.

17 treatment groups]), stroke 1.06 (0.83-1.36), ischaemic heart disease 0.76 (0.60-0.95, p=0.02), and en

18 ed mortality from all major causes of death (ischaemic heart disease 0.81 [0.78-0.85], cerebrovascula

19 95-0.928; cardiovascular 0.911, 0.894-0.928; ischaemic heart disease 0.904, 0.882-0.927; cerebrovascu

20 st of the time 0.98, 95% CI 0.94-1.01), from ischaemic heart disease (0.97, 0.87-1.10), or from cance

21 ion in the number of years of life lost from ischaemic heart disease (10-19% in London, 11-25% in Del

22 population [95% CI -8.16 to 0.80]; p=0.107), ischaemic heart disease (-2.21 per 100,000 [-6.86 to 2.4

23 vourable than those of medical treatment for ischaemic heart disease ($500.41-706.54 per DALY) and HI

24 The leading causes of death in 1990 were ischaemic heart disease (6.3 million deaths), cerebrovas

25 w-and-middle-income countries (1,224,000 for ischaemic heart disease, 623,000 for stroke).

26 /1510) and self-reported physician-diagnosed ischaemic heart disease (686/4006 vs 192/1510) than men

27 chronic obstructive pulmonary disease (60%), ischaemic heart disease (83-89%), and stroke (70-76%).

28 ing cause of death in the region in 2013 was ischaemic heart disease (90.3 deaths per 100 000 people)

29 792,000 (53%) of deaths from ischaemic heart disease and 345,000 (49%) from stroke th

30 assigned to diabetes, 1 490,000 deaths from ischaemic heart disease and 709,000 from stroke were att

31 is the most common clinical manifestation of ischaemic heart disease and a leading cause of mortality

32 cells that could contribute new muscle after ischaemic heart disease and acute myocardial infarction.

33 een implicated in causing excess deaths from ischaemic heart disease and exacerbations of COPD.

34 in terms of hypertension, diabetes mellitus, ischaemic heart disease and hyperlipidemia.

35 with the presence of hypertension, diabetes, ischaemic heart disease and peripheral vascular disease

36 Ischaemic heart disease and stroke collectively killed 1

37 cardiovascular risk factors and with risk of ischaemic heart disease and stroke in adult life.

38 Relative risks for ischaemic heart disease and stroke mortality were from a

39 ntrations of blood glucose on mortality from ischaemic heart disease and stroke worldwide.

40 nd diarrhoea decreased by 45-54% since 1990; ischaemic heart disease and stroke YLLs increased by 17-

41 o all causes, and to cardiovascular disease, ischaemic heart disease, and cancer in 19 496 men and wo

42 y due to all causes, cardiovascular disease, ischaemic heart disease, and cancer.

43 ty before Jan 1, 2012, from all causes, from ischaemic heart disease, and from cancer in women who di

44 ditions such as hypertension, heart failure, ischaemic heart disease, and nephropathy.

45 cular disease as the leading cause, five had ischaemic heart disease, and one had lung cancer (Hong K

46 tients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyop

47 In 2013, the leading cause of YLLs was ischaemic heart disease, and the leading cause of DALYs

48 nary effects of walking in people with COPD, ischaemic heart disease, and those free from chronic car

49 y bypass surgery), angina and/or unspecified ischaemic heart disease as a cause of death; additional

50 gastrointestinal bleeding, and patients with ischaemic heart disease at baseline.

51 age-adjusted and sex-adjusted mortality for ischaemic heart disease, cancer, and a composite of all

52 6 months to compare incident cardiovascular (ischaemic heart disease, cerebral infarction, heart fail

53 he prevalences of type 2 diabetes, dementia, ischaemic heart disease, cerebrovascular disease, and ca

54 stimated the relative risk of mortality from ischaemic heart disease, cerebrovascular disease, chroni

55 e (2.83 [1.29-6.17]), but not with diabetes, ischaemic heart disease, cerebrovascular disease, chroni

56 inatal disorders, unipolar major depression, ischaemic heart disease, cerebrovascular disease, tuberc

57 leading five causes of DALYs were diabetes, ischaemic heart disease, chronic kidney disease, low bac

58 disease, but significantly greater rates for ischaemic heart disease, chronic obstructive pulmonary d

59 RR 3.78, 2.78-5.14), and ischaemic stroke or ischaemic heart disease (combined RR 2.03, 1.66-2.47).

60 of 67 mmol/mol (8.3%), and risk factors for ischaemic heart disease enrolled in the ACCORD trial.

61 f disability-adjusted life-years (DALYs) was ischaemic heart disease for males and lower respiratory

62 material from patients with DCM (n = 21) or ischaemic heart disease (HD; n = 10) and from normal don

63 ociated with a significantly reduced risk of ischaemic heart disease (HR 0.80 [95%CI 0.72-0.87]), cer

64 Ischaemic heart disease, hypertension, diabetes mellitus

65 f alanine aminotransferase (ALT) levels with ischaemic heart disease (IHD) and cardiovascular disease

66 ricular systolic dysfunction had evidence of ischaemic heart disease (IHD) from history or ECG criter

67 are small at birth are at increased risk of ischaemic heart disease (IHD) in later life.

68 ere more than 55,000 vascular deaths (34,000 ischaemic heart disease [IHD], 12,000 stroke, 10,000 oth

69 uring follow-up (myocardial infarction [MI], ischaemic heart disease [IHD], cardiomyopathy, and heart

70 causes, and from cardiovascular disease, and ischaemic heart disease in men and women.

71 oncentration is a modifiable risk factor for ischaemic heart disease in middle-aged people with type

72 mia could substantially increase the risk of ischaemic heart disease in patients with type 2 diabetes

73 nd 1992 and on recall of physician-diagnosed ischaemic heart disease in the 1992 questionnaire.

74 tives had some adverse effect on deaths from ischaemic heart disease in women who smoked 15 or more c

75 les with increased myocardial infarction and ischaemic heart disease, independent of the standard, es

76 Ischaemic heart disease limits oxygen and metabolic subs

77 Ischaemic heart disease, lower respiratory infections, s

78 s from non-communicable diseases--especially ischaemic heart disease, mental disorders such as depres

79 246; 95% CI 0.036, 0.469; p = 0.021) and for ischaemic heart disease (n = 6410; excess relative risk/

80 ors in identification of cause of death were ischaemic heart disease (n=27), pulmonary embolism (11),

81 often described as Alzheimer's disease) and ischaemic heart disease, obesity, hypertension, hyperlip

82 Individuals with ischaemic heart disease or COPD were recruited from exis

83 n; history of cancer, renal disease, stroke, ischaemic heart disease or respiratory disease; statin u

84 nd older with angiographically proven stable ischaemic heart disease or stage 2 Global initiative for

85 for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to com

86 eneous in patients with heart failure due to ischaemic heart disease, possibly indicating variations

87 rom the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study who were aged

88 of the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study, were included

89 rly in life has some persisting influence on ischaemic heart disease risk in adult life.

90 All circulatory-disease and ischaemic-heart-disease risk reduces with increasing tim

91 rction and self-reported physician-diagnosed ischaemic heart disease seen in men whose father's socia

92 hearts of 19 patients with end-stage CHF (12 ischaemic heart disease, seven dilated cardiomyopathy),

93 common non-communicable diseases, including ischaemic heart disease, stroke, chronic obstructive pul

94 Ischaemic heart disease, stroke, chronic obstructive pul

95 t cancer, colorectal cancer, depression, and ischaemic heart disease--that are associated with physic

96 ons for miscoding of important diseases (eg, ischaemic heart disease) to estimate worldwide and regio

97 ients were those aged 18 years or older with ischaemic heart disease undergoing planned stent implant

98 e baseline model were (in descending order): ischaemic heart disease, unipolar major depression, road

99 class on non-fatal myocardial infarction and ischaemic heart disease was only seen in men whose adult

100 The standardized mortality ratio for ischaemic heart disease was significantly elevated for t

101 (6.0%), and in female indivduals (6.1%), but ischaemic heart disease was the leading cause of DALYs i

102 Ischaemic heart disease was the leading cause of DALYs w

103 Overall, ischaemic heart disease was the main reported cause of h

104 Ischaemic heart disease was the top cause of death in th

105 deaths attributable to this risk factor from ischaemic heart disease were in low-and-middle-income co

106 teers, 40 individuals with COPD, and 39 with ischaemic heart disease were recruited.

107 termine basal CRP levels has implications in ischaemic heart disease, where CRP level is an important

108 old woman with advanced heart failure due to ischaemic heart disease who underwent an upgrade from VV

109 lcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working